drugset / Trial / NCT05747508

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05747508

Phase 2 Unknown 85 enrolled Bellerophon
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled dose escalation study to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis on long term oxygen therapy.

Timeline

Start
2017-12-29
Primary completion
2019-11-22
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 30 ug/kg Inhaled
Subject Nitric Oxide Other / unclassified 45 ug/kg Inhaled
Subject Nitric Oxide Other / unclassified 75 ug/kg Inhaled